Though advances have been made in the pharmacological targeting of alternate ubiquitin-regulating enzymes in cancer [61], since the discovery of GS143 and erioflorin no other small molecule inhibitors of βTrCP have been identified. The gene discussed is BTRC; the disease is cancer.